Literature DB >> 2181098

Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations.

A T Pavia1, C R Nichols, D P Green, R V Tauxe, S Mottice, K D Greene, J G Wells, R L Siegler, E D Brewer, D Hannon.   

Abstract

PURPOSE: To describe an outbreak of Escherichia coli O175:H7 infection resulting in a high rate of progression to hemolytic-uremic syndrome, and to attempt to identify predictors of and risk factors for progression.
DESIGN: Case-control study among employees and comparison of daily clinical features in two groups: infected residents with subsequent development of HUS and those who had no complications.
SETTING: Two institutions for retarded persons in Utah. PATIENTS: Twenty residents with E. coli O157:H7 infection (13 culture confirmed, 2 probable, and 5 possible); HUS developed in 8, and 4 died. Thirty-one infected employees (3 with culture-confirmed, 6 with probable, and 22 with possible infection).
MEASUREMENTS AND MAIN RESULTS: In a case-control study among employees, infection was independently associated with eating ground beef from a single lot prepared at several barbecues and with close contact with a resident who had diarrhea. Five of eight residents in whom HUS developed had received trimethoprim-sulfamethoxazole, compared with none of seven who had no subsequent complications (p = 0.026); this finding may reflect antimicrobial treatment of patients with more severe illness. Compared with infected residents without complications, persons with HUS were younger (median age 13 vs 27 years, p = 0.043) and, by the third day of illness, had higher leukocyte counts (median 23.7 X 10(9)/L vs 9.1 X 10(9)/L, p = 0.018) and temperature (median 38.5 degrees C vs 37.0 degrees C, p = 0.016). Leukocytosis peaked on day 4, more than 24 hours before signs of HUS appeared.
CONCLUSIONS: Food-borne outbreaks of E. coli O157:H7 in institutions may have devastating effects. Leukocytosis and fever may precede and predict HUS in patients with E. coli O157:H7 infection.

Entities:  

Mesh:

Year:  1990        PMID: 2181098     DOI: 10.1016/s0022-3476(05)81600-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  52 in total

Review 1.  Bacteriophage control of bacterial virulence.

Authors:  Patrick L Wagner; Matthew K Waldor
Journal:  Infect Immun       Date:  2002-08       Impact factor: 3.441

Review 2.  Management of infectious diarrhoea.

Authors:  A C Casburn-Jones; M J G Farthing
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

3.  Evaluation of a real-time PCR kit for detecting Escherichia coli O157 in bovine fecal samples.

Authors:  James L Bono; James E Keen; Laura C Miller; James M Fox; Carol G Chitko-McKown; Michael P Heaton; William W Laegreid
Journal:  Appl Environ Microbiol       Date:  2004-03       Impact factor: 4.792

4.  Escherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.

Authors:  P C Rowe
Journal:  Can J Infect Dis       Date:  1995-03

5.  Modeling and predicting the simultaneous growth of Escherichia coli O157:H7 and ground beef background microflora for various enrichment protocols.

Authors:  A Vimont; C Vernozy-Rozand; M P Montet; C Lazizzera; C Bavai; M-L Delignette-Muller
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

6.  CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.

Authors:  James K Roche; Tiffany R Keepers; Lisa K Gross; Regina M Seaner; Tom G Obrig
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 7.  Leukocytosis as a predictor for progression to haemolytic uraemic syndrome in Escherichia coli O157:H7 infection.

Authors:  M A Anjay; P Anoop; A Britland
Journal:  Arch Dis Child       Date:  2007-09       Impact factor: 3.791

8.  Terminology of hemolytic-uremic syndrome.

Authors:  R N Srivastava
Journal:  Pediatr Nephrol       Date:  1991-09       Impact factor: 3.714

Review 9.  Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Authors:  Saul Tzipori; Abhineet Sheoran; Donna Akiyoshi; Arthur Donohue-Rolfe; Howard Trachtman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Association of Escherichia coli O157:H7 tir polymorphisms with human infection.

Authors:  James L Bono; James E Keen; Michael L Clawson; Lisa M Durso; Michael P Heaton; William W Laegreid
Journal:  BMC Infect Dis       Date:  2007-08-24       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.